Details for Patent: 7,776,358
✉ Email this page to a colleague
Which drugs does patent 7,776,358 protect, and when does it expire?
Patent 7,776,358 protects VENLAFAXINE BESYLATE and is included in one NDA.
This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,776,358
Title: | Extended release venlafaxine besylate tablets |
Abstract: | Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s). |
Inventor(s): | Cucala Escoi; Joan (Barcelona, ES), Gallego Luengo; Montserrat (Barcelona, ES), Margallo Lana; Inocencia (Barcelona, ES) |
Assignee: | Synthon IP Inc. (Gainesville, VA) |
Application Number: | 10/895,984 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Device; Dosage form; |
Drugs Protected by US Patent 7,776,358
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Almatica | VENLAFAXINE BESYLATE | venlafaxine besylate | TABLET, EXTENDED RELEASE;ORAL | 215429-001 | Jun 29, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |